Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: Sources of variability and preliminary observations on relations with clinical response

Giovanna Jannuzzi, Giuliana Gatti, Paolo Magni, Edoardo Spina, Roberta Pacifici, Piergiorgio Zuccaro, Riccardo Torta, Laura Guarneri, Emilio Perucca

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Factors affecting the plasma concentrations of the R- and S-enantiomers of fluoxetine and norfluoxetine were investigated in 131 adult patients receiving long-term fluoxetine, of 10 to 60 mg/d (mean, 24 ± 10 mg/d). Plasma concentration values (geometric means, CI 95%) in these patients were 186 (156, 223) nmol/L for S-fluoxetine, 67 (58, 77) nmol/L for R-fluoxetine, 247 (212, 287) nmol/L for S-norfluoxetine, and 118 (102, 137) nmol/L for R-norfluoxetine. The difference between the concentrations of the respective R- and S-enantiomers was statistically significant (P <0.0001) for both the parent drug and the demethylated metabolite. A significant correlation was found between the concentrations of each enantiomer and the prescribed daily dosage (r = 0.44, P <0.0001 for S-fluoxetine; r = 0.48, P <0.0001 for R-fluoxetine; r = 0.36, P <0.0001 for S-norfluoxetine; r = 0.32, P = 0.0003 for R-norfluoxetine), but the variability in concentration at any given dosage was considerable. When an iterative model based on multiple polynomial regressions was applied to determine the potential contributions of dosage, age, gender, body weight, and concomitant medication to the variability in the plasma concentration of the enantiomers, dosage was consistently found to provide the greatest predictive value. The predictive value of the model could be consistently improved when concentrations of other enantiomers were included as covariates. Of 58 patients with depressive symptoms for whom evaluation of clinical response (CGI scale) was available, 33 (57%) responded favorably to treatment. The plasma levels of individual enantiomers and of the active moiety (ActM, sum of the concentrations of R-fluoxetine, S-fluoxetine, and S-norfluoxetine) in these patients did not differ significantly from those found in patients with unsatisfactory therapeutic response. Likewise, the concentrations of individual enantiomers and of the ActM were similar in patients with or without adverse effects. Overall, these results demonstrate that the pharmacokinetics of fluoxetine and norfluoxetine exhibit marked stereoselectivity and considerable interpatient variability, which could not be explained by differences in gender, age, or comedication. In addition, a considerable variability was found in the enantiomers' concentrations associated with a favorable therapeutic response.

Original languageEnglish
Pages (from-to)616-627
Number of pages12
JournalTherapeutic Drug Monitoring
Volume24
Issue number5
DOIs
Publication statusPublished - Oct 2002

Fingerprint

Enantiomers
Fluoxetine
Plasmas
norfluoxetine
Stereoselectivity
Pharmacokinetics
Symptom Assessment
Metabolites
Therapeutics
Parents
Body Weight
Polynomials
Depression

Keywords

  • Enantiomers
  • Fluoxetine
  • Norfluoxetine
  • Population pharmacokinetics
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine : Sources of variability and preliminary observations on relations with clinical response. / Jannuzzi, Giovanna; Gatti, Giuliana; Magni, Paolo; Spina, Edoardo; Pacifici, Roberta; Zuccaro, Piergiorgio; Torta, Riccardo; Guarneri, Laura; Perucca, Emilio.

In: Therapeutic Drug Monitoring, Vol. 24, No. 5, 10.2002, p. 616-627.

Research output: Contribution to journalArticle

Jannuzzi, Giovanna ; Gatti, Giuliana ; Magni, Paolo ; Spina, Edoardo ; Pacifici, Roberta ; Zuccaro, Piergiorgio ; Torta, Riccardo ; Guarneri, Laura ; Perucca, Emilio. / Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine : Sources of variability and preliminary observations on relations with clinical response. In: Therapeutic Drug Monitoring. 2002 ; Vol. 24, No. 5. pp. 616-627.
@article{30cfd43da7fb472a94bb980b773e1f51,
title = "Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: Sources of variability and preliminary observations on relations with clinical response",
abstract = "Factors affecting the plasma concentrations of the R- and S-enantiomers of fluoxetine and norfluoxetine were investigated in 131 adult patients receiving long-term fluoxetine, of 10 to 60 mg/d (mean, 24 ± 10 mg/d). Plasma concentration values (geometric means, CI 95{\%}) in these patients were 186 (156, 223) nmol/L for S-fluoxetine, 67 (58, 77) nmol/L for R-fluoxetine, 247 (212, 287) nmol/L for S-norfluoxetine, and 118 (102, 137) nmol/L for R-norfluoxetine. The difference between the concentrations of the respective R- and S-enantiomers was statistically significant (P <0.0001) for both the parent drug and the demethylated metabolite. A significant correlation was found between the concentrations of each enantiomer and the prescribed daily dosage (r = 0.44, P <0.0001 for S-fluoxetine; r = 0.48, P <0.0001 for R-fluoxetine; r = 0.36, P <0.0001 for S-norfluoxetine; r = 0.32, P = 0.0003 for R-norfluoxetine), but the variability in concentration at any given dosage was considerable. When an iterative model based on multiple polynomial regressions was applied to determine the potential contributions of dosage, age, gender, body weight, and concomitant medication to the variability in the plasma concentration of the enantiomers, dosage was consistently found to provide the greatest predictive value. The predictive value of the model could be consistently improved when concentrations of other enantiomers were included as covariates. Of 58 patients with depressive symptoms for whom evaluation of clinical response (CGI scale) was available, 33 (57{\%}) responded favorably to treatment. The plasma levels of individual enantiomers and of the active moiety (ActM, sum of the concentrations of R-fluoxetine, S-fluoxetine, and S-norfluoxetine) in these patients did not differ significantly from those found in patients with unsatisfactory therapeutic response. Likewise, the concentrations of individual enantiomers and of the ActM were similar in patients with or without adverse effects. Overall, these results demonstrate that the pharmacokinetics of fluoxetine and norfluoxetine exhibit marked stereoselectivity and considerable interpatient variability, which could not be explained by differences in gender, age, or comedication. In addition, a considerable variability was found in the enantiomers' concentrations associated with a favorable therapeutic response.",
keywords = "Enantiomers, Fluoxetine, Norfluoxetine, Population pharmacokinetics, Therapeutic drug monitoring",
author = "Giovanna Jannuzzi and Giuliana Gatti and Paolo Magni and Edoardo Spina and Roberta Pacifici and Piergiorgio Zuccaro and Riccardo Torta and Laura Guarneri and Emilio Perucca",
year = "2002",
month = "10",
doi = "10.1097/00007691-200210000-00006",
language = "English",
volume = "24",
pages = "616--627",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine

T2 - Sources of variability and preliminary observations on relations with clinical response

AU - Jannuzzi, Giovanna

AU - Gatti, Giuliana

AU - Magni, Paolo

AU - Spina, Edoardo

AU - Pacifici, Roberta

AU - Zuccaro, Piergiorgio

AU - Torta, Riccardo

AU - Guarneri, Laura

AU - Perucca, Emilio

PY - 2002/10

Y1 - 2002/10

N2 - Factors affecting the plasma concentrations of the R- and S-enantiomers of fluoxetine and norfluoxetine were investigated in 131 adult patients receiving long-term fluoxetine, of 10 to 60 mg/d (mean, 24 ± 10 mg/d). Plasma concentration values (geometric means, CI 95%) in these patients were 186 (156, 223) nmol/L for S-fluoxetine, 67 (58, 77) nmol/L for R-fluoxetine, 247 (212, 287) nmol/L for S-norfluoxetine, and 118 (102, 137) nmol/L for R-norfluoxetine. The difference between the concentrations of the respective R- and S-enantiomers was statistically significant (P <0.0001) for both the parent drug and the demethylated metabolite. A significant correlation was found between the concentrations of each enantiomer and the prescribed daily dosage (r = 0.44, P <0.0001 for S-fluoxetine; r = 0.48, P <0.0001 for R-fluoxetine; r = 0.36, P <0.0001 for S-norfluoxetine; r = 0.32, P = 0.0003 for R-norfluoxetine), but the variability in concentration at any given dosage was considerable. When an iterative model based on multiple polynomial regressions was applied to determine the potential contributions of dosage, age, gender, body weight, and concomitant medication to the variability in the plasma concentration of the enantiomers, dosage was consistently found to provide the greatest predictive value. The predictive value of the model could be consistently improved when concentrations of other enantiomers were included as covariates. Of 58 patients with depressive symptoms for whom evaluation of clinical response (CGI scale) was available, 33 (57%) responded favorably to treatment. The plasma levels of individual enantiomers and of the active moiety (ActM, sum of the concentrations of R-fluoxetine, S-fluoxetine, and S-norfluoxetine) in these patients did not differ significantly from those found in patients with unsatisfactory therapeutic response. Likewise, the concentrations of individual enantiomers and of the ActM were similar in patients with or without adverse effects. Overall, these results demonstrate that the pharmacokinetics of fluoxetine and norfluoxetine exhibit marked stereoselectivity and considerable interpatient variability, which could not be explained by differences in gender, age, or comedication. In addition, a considerable variability was found in the enantiomers' concentrations associated with a favorable therapeutic response.

AB - Factors affecting the plasma concentrations of the R- and S-enantiomers of fluoxetine and norfluoxetine were investigated in 131 adult patients receiving long-term fluoxetine, of 10 to 60 mg/d (mean, 24 ± 10 mg/d). Plasma concentration values (geometric means, CI 95%) in these patients were 186 (156, 223) nmol/L for S-fluoxetine, 67 (58, 77) nmol/L for R-fluoxetine, 247 (212, 287) nmol/L for S-norfluoxetine, and 118 (102, 137) nmol/L for R-norfluoxetine. The difference between the concentrations of the respective R- and S-enantiomers was statistically significant (P <0.0001) for both the parent drug and the demethylated metabolite. A significant correlation was found between the concentrations of each enantiomer and the prescribed daily dosage (r = 0.44, P <0.0001 for S-fluoxetine; r = 0.48, P <0.0001 for R-fluoxetine; r = 0.36, P <0.0001 for S-norfluoxetine; r = 0.32, P = 0.0003 for R-norfluoxetine), but the variability in concentration at any given dosage was considerable. When an iterative model based on multiple polynomial regressions was applied to determine the potential contributions of dosage, age, gender, body weight, and concomitant medication to the variability in the plasma concentration of the enantiomers, dosage was consistently found to provide the greatest predictive value. The predictive value of the model could be consistently improved when concentrations of other enantiomers were included as covariates. Of 58 patients with depressive symptoms for whom evaluation of clinical response (CGI scale) was available, 33 (57%) responded favorably to treatment. The plasma levels of individual enantiomers and of the active moiety (ActM, sum of the concentrations of R-fluoxetine, S-fluoxetine, and S-norfluoxetine) in these patients did not differ significantly from those found in patients with unsatisfactory therapeutic response. Likewise, the concentrations of individual enantiomers and of the ActM were similar in patients with or without adverse effects. Overall, these results demonstrate that the pharmacokinetics of fluoxetine and norfluoxetine exhibit marked stereoselectivity and considerable interpatient variability, which could not be explained by differences in gender, age, or comedication. In addition, a considerable variability was found in the enantiomers' concentrations associated with a favorable therapeutic response.

KW - Enantiomers

KW - Fluoxetine

KW - Norfluoxetine

KW - Population pharmacokinetics

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=0036786739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036786739&partnerID=8YFLogxK

U2 - 10.1097/00007691-200210000-00006

DO - 10.1097/00007691-200210000-00006

M3 - Article

C2 - 12352933

AN - SCOPUS:0036786739

VL - 24

SP - 616

EP - 627

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 5

ER -